Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AN OPEN-LABEL STUDY OF ALTO-300 IN ADULTS WITH MAJOR DEPRESSIVE DISORDER

Next Previous
X
Search
Trial Profile

AN OPEN-LABEL STUDY OF ALTO-300 IN ADULTS WITH MAJOR DEPRESSIVE DISORDER

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 May 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Agomelatine (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Alto Neuroscience

    • Most Recent Events

    • 09 May 2024 According to an Alto Neuroscience media release, company announced upcoming data presentations that highlight the companys precision psychiatry pipeline and biomarker based analyses at the Society of Biological Psychiatry (SOBP), to take place May 9 to11 in Austin, TX.
    • 07 Dec 2023 Results published in the Alto Neuroscience Media Release
    • 04 Dec 2023 According to an Alto Neuroscience Media Release, positive results from this trial were presented at the 62nd Annual Meeting of the American College of Neuropsychopharmacology (ACNP), demonstrating clinically meaningful improvements and favorable safety and tolerability in patients with major depressive disorder (MDD).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top